Themed "Global IVD Innovation & Cross-Regional Integration," this groundbreaking event brings together distinguished experts from around the world to explore the future of diagnostics.

August 25, Mindray (300760.SZ) announced financial results for the first half ended June 30, 2021. The first-half sales of CNY 12.778 billion increased 20.96% year-on-year. The net earnings attributable to common stockholders was CNY 4.344 billion, increasing 25.79% than the one in the last year.

AccessDx Holdings said Wednesday that it has acquired 2bPrecise, a service and technology provider that integrates genetic and genomic test results into electronic health records, from EHR giant Allscripts Healthcare Solutions for an undisclosed amount.

Becton Dickinson announced Wednesday that it has received US Food and Drug Administration approval for its automated, sample-to-answer, high-throughput BD Cor system along with the BD Onclarity HPV Assay for extended genotyping of human papillomavirus.

On August 20, Fosun Diagnostics, a holding subsidiary of Fosun Pharma, signed the investment agreement with Suzhou Abcarta. After the completion of the transaction, Fosun Diagnostics will hold about 58.67% equity of Suzhou Abcarta.

Genetron Health on Tuesday reported a 38 percent year-over-year increase in its second quarter revenues amid strong growth in sales from its LDT and IVD segments.

Cerba Research and ACT Genomics said on Tuesday that they have formed a joint venture to provide clinical trial services to clients throughout Asia Pacific through a new laboratory facility in Taiwan.

Recently, SARS-CoV-2 Neutralizing Antibody Rapid Test (Fluorescence Dry Quantitative Immunoassay) developed by Joinstar Biomedical Technology Co., Ltd. and Nanshan Pharmaceutical Research Institute of Guangdong province was officially sold to overseas markets.

On August 21, TELLGEN posted a 157.93% year-over-year increase on continued demand for its tumor and autoimmunity test.

AnPac Bio-Medical Science, a cancer screening and detection company, said on Monday that it has filed for registration testing of its Class III, multi-cancer detection device with China's National Medical Products Administration.

Point-of-care diagnostics firm LumiraDx and special purpose acquisition company CA Healthcare Acquisition said on Monday that they have revised the terms of their previously announced merger to lower the equity value of the combined company.